nach oben

Calcified Tissue International

Erschienen in:

01.11.2010

Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation

verfasst von: M. Sridharan, J. Cheung, A. E. Moore, M. L. Frost, W. D. Fraser, I. Fogelman, G. Hampson

Erschienen in: Calcified Tissue International | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Uncertainties exist regarding whether FGF-23 production is influenced by PTH and its involvement in bone formation. We evaluated FGF-23 response and its relation to changes in biomarkers of bone formation following intermittent PTH treatment. Twenty-seven women with a mean [SD] age of 75.8 [5.4] years with postmenopausal osteoporosis were treated with PTH(1–34) for 18 months. Bone mineral density (BMD) was measured at 6 and 18 months at the lumbar spine (LS) and total hip (TH). Blood samples were obtained at baseline, 1–3, 6–9, and 12–18 months. Serum calcium, phosphate, PTH, 25(OH)vitamin D, 1,25(OH)₂vitamin D, markers of bone turnover, FGF-23, and sclerostin were measured. BMD increased at both the LS (11.6%, P < 0.001) and TH (2.5%, P < 0.01). The bone formation marker P1NP increased early (baseline mean [SD] 39.9 [24.4] μg/l, 1–3 months 88 [37.9] μg/l; P < 0.001) and remained higher than baseline throughout 18 months. FGF-23 also increased, with a peak response at 6–9 months (increase 65%, P = 0.002). Serum phosphate remained stable. A significant increase in 1.25(OH)₂vitamin D (P = 0.02) was seen at 1–3 months only. A small but significant reduction in sclerostin was seen at 6–9 (P = 0.02) and 12–18 months (P = 0.06). There was a positive correlation between changes in P1NP and FGF-23 (6–9 months r = 0.78, P < 0.001). FGF-23 is increased by intermittent PTH(1–34). This is related to early changes in P1NP, suggesting that the skeletal effects of PTH may involve FGF-23. Further studies are required to elucidate this.

Consortium ADHR (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nat Genet 26:345–348CrossRef

Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Tamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphataemia. N Engl J Med 348:1656–1663CrossRefPubMed

Juppner H (2007) Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 11(Suppl 1):S3–S22CrossRefPubMed

Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMed

Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101–E1109CrossRefPubMed

Collins MT, Linsaay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK (2005) Fibroblast growth factor-23 is regulated by 1alpha, 25-dihydroxyvitamin D. J Bone Miner Res 20:1944–1950CrossRefPubMed

Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, JSl Finkelstein (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187–1196CrossRefPubMed

Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M (2009) Fgf-23 decreases renal Na Pi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297:F282–F291CrossRefPubMed

Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315CrossRefPubMed

10.

Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688CrossRefPubMed

11.

Tebben PJ, Singh RJ, Clarke BL, Kumar R (2004) Fibroblast growth factor 23, parathyroid hormone, and 1alpha, 25-dIhydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79:1508–1513CrossRefPubMed

12.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481–487PubMed

13.

Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178CrossRefPubMed

14.

Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D (2008) Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73:102–107CrossRefPubMed

15.

Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone. doi:10.1016/j.bone.2009.08.008

16.

Daji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T (2009) Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron 111:61–68CrossRef

17.

Marsell R, Grundberg E, Krajisnik T, Mallmin H, Karlsson M, Mellstrom D, Orwoll E, Ohlsson C, Jonsson KB, Ljunggren O, Larsson TE (2008) Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 158:125–129CrossRefPubMed

18.

Hasegawa H, Shimada T, Yamazaki Y (2004) Parathyroid-dependent and -independent mechanism to elevate serum concentration of FGF-23. J. Am Soc Nephrol 15:267A

19.

Burnett-Bowie SM, Henao MP, Dere ME, Alaee H, Leder BZ (2009) Effects of hPTH(1–34) infusion on circulating serum phosphate, 1, 25-dihydroxyvitamin D and FGF23 levels in healthy men. J Bone Miner Res 24:1681–1685CrossRefPubMed

20.

Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40:1565–1573CrossRefPubMed

21.

Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948CrossRefPubMed

22.

Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B (2008) Genetic evidence of serum phosphate-independent functions of fgf-23 on bone. PLOS Genet 4:e10000154CrossRef

23.

Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB (2009) Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517CrossRefPubMed

24.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed

25.

Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434–1446CrossRefPubMed

26.

Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148–158CrossRefPubMed

27.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O’Brien CA, Manolagas SC, Jilka RL (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577–4583CrossRefPubMed

28.

O’Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3:e2942CrossRefPubMed

29.

Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, Pound S, Rappaport I, Robertson D, Semple Y, Slane P, Whitworth C, Williams B (2007) UK consensus conference on early chronic kidney disease–6 and 7. Nephrol Dial Transplant 22:2455–2457CrossRefPubMed

30.

Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP (2008) Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 23:721–729CrossRefPubMed

31.

Chen P, Miller PD, Delmas PD, Misurki DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785–1790CrossRefPubMed

32.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793CrossRefPubMed

33.

Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefPubMed

34.

Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C (2010) Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab 28:68–76CrossRefPubMed

35.

Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, Sudhaker Rao D, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350CrossRefPubMed

36.

Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by 3 commercial assays. Ann Clin Biochem 44:463–466CrossRefPubMed

37.

Bergwitz C, Juppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D and FGF-23. Annu Rev Med 61:91–104CrossRefPubMed

38.

Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey O (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692PubMed

39.

Rhee Y, Farrow E, Lee R, Bivi N, Lazcano V, Plotkin L, White K, Bellido T (2009) FGF23 expression is upregulated by PTH receptor activation in osteocytes in vitro and in vivo: a parathyroid-bone link influencing the endocrine function of osteocytes. J Bone Miner Res 24 (suppl 1). http://www.asbmr.org/ Meetings/Annual meeting/A09001860 (accessed March 6, 2010)

40.

Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, Mc Cormick KL (2008) Hypophosphatemia with elevations in FGF-23 in a child with Jansen’s metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94:17–20CrossRefPubMed

41.

Walton RJ, Russell RG, Smith R (1975) Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 49:45–56PubMed

42.

Bonjour JP, Troehler U, Preston C, Fleisch H (1978) Parathyroid hormone and renal handling of P_i: effect of dietary P_i and diphosphonates. Am J Physiol Renal Physiol 234:F497–F505

43.

Wesseling-Perry K, Harkins GC, Wang H, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Juppner H, Salusky IB (2010) The calcemic response to continuous parathyroid hormone (PTH) (1–34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH (7–84). J Clin Endocrinol Metab 95:2772–2780CrossRefPubMed

44.

Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D (2009) Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150:4835–4845CrossRefPubMed

45.

Bellido T (2006) Downregulation of SOST/Sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes. J Musculoskelet Neuronal Interact 6:358–359PubMed

Titel: Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation
verfasst von: M. Sridharan
J. Cheung
A. E. Moore
M. L. Frost
W. D. Fraser
I. Fogelman
G. Hampson
Publikationsdatum: 01.11.2010
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 5/2010
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-010-9414-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women

Contribution of Mineral to Bone Structural Behavior and Tissue Mechanical Properties

The Expression of IL-6 by Osteoblasts Is Increased in Healthy Elderly Individuals: Stimulated Proliferation and Differentiation Are Unaffected by Age

Assessment of Bone Microarchitecture in Chronic Kidney Disease: A Comparison of 2D Bone Texture Analysis and High-Resolution Peripheral Quantitative Computed Tomography at the Radius and Tibia

Potential of Resveratrol Analogues as Antagonists of Osteoclasts and Promoters of Osteoblasts